Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta-Analysis

IF 1.9 4区医学 Q2 OTORHINOLARYNGOLOGY

Clinical Otolaryngology Pub Date : 2026-08-03 Epub Date: 2026-06-21 DOI:10.1111/coa.70134

Yu Hsin Lin, Hsin Yi Huang, Wan-Lun Hsu, Li-Jen Liao

{"title":"Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta-Analysis","authors":"Yu Hsin Lin, Hsin Yi Huang, Wan-Lun Hsu, Li-Jen Liao","doi":"10.1111/coa.70134","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The haemoglobin–albumin–lymphocyte–platelet (HALP) score is an inflammation- and nutrition-related biomarker derived from routine blood tests, but its prognostic value in head and neck cancer (HNC) has not been quantitatively synthesized. This systematic review and meta-analysis aimed to evaluate the association between pretreatment HALP and survival outcomes in HNC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>PubMed, Embase and Web of Science were searched to 24 January 2026 for cohort studies reporting hazard ratios (HRs) for survival outcomes by pretreatment HALP in HNC. Reviews, case reports, conference abstracts without full text, and studies lacking survival data were excluded. Random-effects meta-analysis was performed and risk of bias was assessed using QUIPS. The review was prospectively registered in the Open Science Framework.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Six retrospective cohort studies (1759 patients) were included. Higher pretreatment HALP was associated with improved overall survival (pooled HR 0.52, 95% CI 0.41–0.67; <i>I</i><sup>2</sup> = 17.6%) and disease-free survival (pooled HR 0.60, 95% CI 0.47–0.76; <i>I</i><sup>2</sup> = 0.0%). After excluding the metastatic cohort, the pooled overall survival estimate remained similar (HR 0.56, 95% CI 0.45–0.70; <i>I</i><sup>2</sup> = 0.0%), and leave-one-out analyses showed stable estimates (HR range 0.48–0.56).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Higher pretreatment HALP is associated with favourable survival in HNC. However, reported cutoff values for HALP have been inconsistent across studies. HALP might be helpful for clinicians in evaluating the prognosis of HNC patients.</p>\n </section>\n </div>","PeriodicalId":10431,"journal":{"name":"Clinical Otolaryngology","volume":"51 5","pages":"635-643"},"PeriodicalIF":1.9000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/coa.70134","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

The haemoglobin–albumin–lymphocyte–platelet (HALP) score is an inflammation- and nutrition-related biomarker derived from routine blood tests, but its prognostic value in head and neck cancer (HNC) has not been quantitatively synthesized. This systematic review and meta-analysis aimed to evaluate the association between pretreatment HALP and survival outcomes in HNC.

Methods

PubMed, Embase and Web of Science were searched to 24 January 2026 for cohort studies reporting hazard ratios (HRs) for survival outcomes by pretreatment HALP in HNC. Reviews, case reports, conference abstracts without full text, and studies lacking survival data were excluded. Random-effects meta-analysis was performed and risk of bias was assessed using QUIPS. The review was prospectively registered in the Open Science Framework.

Results

Six retrospective cohort studies (1759 patients) were included. Higher pretreatment HALP was associated with improved overall survival (pooled HR 0.52, 95% CI 0.41–0.67; I² = 17.6%) and disease-free survival (pooled HR 0.60, 95% CI 0.47–0.76; I² = 0.0%). After excluding the metastatic cohort, the pooled overall survival estimate remained similar (HR 0.56, 95% CI 0.45–0.70; I² = 0.0%), and leave-one-out analyses showed stable estimates (HR range 0.48–0.56).

Conclusions

Higher pretreatment HALP is associated with favourable survival in HNC. However, reported cutoff values for HALP have been inconsistent across studies. HALP might be helpful for clinicians in evaluating the prognosis of HNC patients.

查看原文本刊更多论文

血红蛋白-白蛋白-淋巴细胞-血小板评分在头颈癌中的预后价值：一项系统综述和荟萃分析。

目的：血红蛋白-白蛋白-淋巴细胞-血小板（HALP）评分是一种来自常规血液检查的炎症和营养相关的生物标志物，但其在头颈癌（HNC）中的预后价值尚未定量合成。本系统综述和荟萃分析旨在评估预处理HALP与HNC患者生存结局之间的关系。方法：检索PubMed、Embase和Web of Science，检索截至2026年1月24日报道预处理HALP对HNC患者生存结果风险比（hr）的队列研究。排除综述、病例报告、没有全文的会议摘要和缺乏生存数据的研究。进行随机效应荟萃分析，并使用QUIPS评估偏倚风险。该综述有望在开放科学框架中注册。结果：纳入6项回顾性队列研究（1759例患者）。较高的预处理HALP与改善的总生存期（合并HR 0.52, 95% CI 0.41-0.67; I2 = 17.6%）和无病生存期（合并HR 0.60, 95% CI 0.47-0.76; I2 = 0.0%）相关。在排除转移队列后，合并总生存率估计保持相似（HR 0.56, 95% CI 0.45-0.70; I2 = 0.0%），并且留一分析显示稳定的估计（HR范围0.48-0.56）。结论：高预处理HALP与HNC患者良好的生存率相关。然而，报告的HALP临界值在不同的研究中并不一致。HALP可能有助于临床医生评估HNC患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Otolaryngology 医学-耳鼻喉科学

CiteScore

4.00

自引率

4.80%

发文量

106

审稿时长

>12 weeks

期刊介绍： Clinical Otolaryngology is a bimonthly journal devoted to clinically-oriented research papers of the highest scientific standards dealing with: current otorhinolaryngological practice audiology, otology, balance, rhinology, larynx, voice and paediatric ORL head and neck oncology head and neck plastic and reconstructive surgery continuing medical education and ORL training The emphasis is on high quality new work in the clinical field and on fresh, original research. Each issue begins with an editorial expressing the personal opinions of an individual with a particular knowledge of a chosen subject. The main body of each issue is then devoted to original papers carrying important results for those working in the field. In addition, topical review articles are published discussing a particular subject in depth, including not only the opinions of the author but also any controversies surrounding the subject. • Negative/null results In order for research to advance, negative results, which often make a valuable contribution to the field, should be published. However, articles containing negative or null results are frequently not considered for publication or rejected by journals. We welcome papers of this kind, where appropriate and valid power calculations are included that give confidence that a negative result can be relied upon.